Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation

Addictive Behaviors

Volumn 36, Issue 6, 2011, Pages 584-589

  Roman, Paul M ^a   Abraham, Amanda J ^a   Knudsen, Hannah K ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Acamprosate; Buprenorphine; Disulfiram; Injectable naltrexone; Medication assisted treatment; Tablet naltrexone

Indexed keywords

ACAMPROSATE; BUPRENORPHINE; DISULFIRAM; NALTREXONE;

ARTICLE; DRUG DEPENDENCE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; SUBSTANCE ABUSE;

ALCOHOL DETERRENTS; BUPRENORPHINE; DISULFIRAM; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; PATIENT EDUCATION AS TOPIC; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS; TAURINE; UNITED STATES;

EID: 79953163674     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addbeh.2011.01.032     Document Type: Article

References (27)

1. Abraham A.J., Ducharme L.J., Roman P.M. Counselor attitudes toward pharmacotherapies for alcohol dependence. Journal of Studies on Alcohol and Drugs 2009, 70:628-635.
2. Abraham A.J., Knudsen H.K., Rothrauff T.C., Roman P.M. The adoption of alcohol pharmacotherapies in the Clinical Trials Network: The influence of research network participation. Journal of Substance Abuse Treatment 2010, 38:275-283.
3. Abraham A.J., Roman P.M. Early adoption of injectable naltrexone for alcohol use disorders: Findings from the private treatment sector. Journal of Studies on Alcohol and Drugs 2010, 71:460-466.
4. Ducharme L.J., Knudsen H.K., Roman P.M. Trends in the adoption of medications for alcohol dependence. Journal of Clinical Psychopharmacology 2006, 26:S13-S19.
5. Ducharme L.J., Knudsen H.K., Roman P.M., Johnson A.J. Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. Journal of Substance Abuse Treatment 2007, 32:321-329.
6. Fiellin D.A., Pantalon M.V., Chawarski M.C., Moore B.A., Sullivan L.E., O'Connor P.G., et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. New England Journal of Medicine 2006, 355:365-374.
7. Hanson G.R., Leshner A.I., Tai B. Putting drug abuse research to use in real-life settings. Journal of Substance Abuse Treatment 2002, 23:69-70.
8. Knudsen H.K., Abraham A.J., Johnson J.A., Roman P.M. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 2009, 37:307-312.
9. Knudsen H.K., Ducharme L.J., Roman P.M. Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment 2006, 30:363-373.
10. Knudsen H.K., Ducharme L.J., Roman P.M. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug and Alcohol Dependence 2007, 87:164-174.
11. Knudsen H.K., Ducharme L.J., Roman P.M., Link T. Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. Journal of Substance Abuse Treatment 2005, 29:95-106.
12. Knudsen H.K., Roman P.M., Ducharme L.J., Johnson J.A. Organizational predictors of pharmacological innovation adoption: The case of disulfiram. Journal of Drug Issues 2005, 35:559-574.
13. Knudsen H.K., Roman P.M., Oser C.B. Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. Journal of Addiction Medicine 2010, 4:99-107.
14. Knudsen, H.K., Abraham, A.J., & Oser, C.B. (under review). Barriers to the implementation of medication-assisted treatment for substance use disorder: The important of funding policies and medical infrastructure. Evaluation and Program Planning.
15. Mee-Lee D.L., Gartner L., Miller M.M., Shulman G.D., Wilford B.B. Patient placement criteria for the treatment of substance-related disorders 2006, American Society of Addiction Medicine, Chevy Chase, MD. 2nd ed.
16. McCarty D., Gustafson D., Capoccia V.A., Cotter F. Improving care for the treatment of alcohol and drug disorders. Journal of Behavioral Health Services & Research 2009, 36:52-60.
17. Milne S.H., Blum T.C., Roman P.M. Quality management in a health care setting: A study of substance abuse treatment centers. Advances in the Management of Organizational Quality 2000, 5:215-248.
18. Montoya I.D., Schroeder J.R., Preston K.L., Covi L., Umbricht A., Contoreggi C., et al. Influence of psychotherapy attendance on buprenorphine treatment outcome. Journal of Substance Abuse Treatment 2000, 28:247-254.
19. National Institute on Drug Abuse Principles of drug addiction treatment: A research-based guide (Publication 00-4180) 2000, Substance Abuse and Mental Health Services Administration, Rockville, MD.
20. National Quality Forum. (2007). National voluntary consensus standards for the treatment of substance use conditions: Evidence-based treatment practices. Retrieved on January 4, 2011. Available online at: http://www.qualityforum.org/Publications/2007/09/National_Voluntary_Consensus_Standards_for_the_Treatment_of_Substance_Use_Conditions__Evidence-Based_Treatment_Practices.aspx.
21. O'Connor P.G., Nyquist J.G., McLellan A.T. Integrating addiction medicine into graduate medical education in primary care: The time has come. Annals of Internal Medicine 2011, 154:56-59.
22. Oser C.B., Roman P.M. Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers. Journal of Studies on Alcohol and Drugs 2007, 68:852-886.
23. Oser C.B., Roman P.M. A categorical typology of naltrexone-adopting private substance abuse treatment centers. Journal of Substance Abuse Treatment 2008, 34:433-442.
24. Roman P.M., Abraham A.J., Rothrauff T.R., Knudsen H.K. A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 2010, 38:S44-S52.
25. Roman P.M., Johnson J.A. Adoption and implementation of new technologies in substance abuse treatment. Journal of Substance Abuse Treatment 2002, 22:211-218.
26. Sullivan L.E., Chawarski M., O'Connor P.G., Schottenfeld R.S., Fiellin D.A. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment?. Drug and Alcohol Dependence 2005, 79:113-116.
27. White W.L. Slaying the dragon: The history of addiction treatment and recovery in America 1998, Chestnut Health Systems/Lighthouse Institute, Bloomington, IL.